Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 26 | ECE2011 | Next issue

13th European Congress of Endocrinology

Symposia

New developments in the therapy for NETs

ea0026s10.1 | New developments in the therapy for NETs | ECE2011

New developments in the therapy for NETs: risk stratification

Pavel M

Neuroendocrine tumors (NETs) represent a rare and diverse group of tumors with predominant location in the gastro-entero-pancreatic and bronchopulmonary system. At initial diagnosis 50% of the patients present with metastatic disease whereas more than 80% develop metastases in the course of the disease with liver metastases as the most frequent ones. In consideration of the variable and sometimes indolent tumor growth behaviour, risk stratification is an important need for the...

ea0026s10.3 | New developments in the therapy for NETs | ECE2011

New developments in the therapy for NETs: new drugs including mTOR inhibitors

Grozinsky-Glasberg Simona

Mammalian target of rapamycin (mTOR), a main serine/threonine protein kinase in the phosphoinositide 3-kinase (PI3K)/Akt/p70S6K signalling pathway, is an important intracellular mediator involved in multiple cellular functions including proliferation, differentiation, apoptosis, tumorigenesis, angiogenesis, and also longevity.Recent studies indicate that mTOR is central in the integration of a multitude of signalling pathways activated by growth factors ...